EMMANUEL BARIAS

Allopathic & Osteopathic Physicians|Family Medicine OAKHURST, NJ NPI 1316998024

General Payments — all program years on this page

$4,772.74

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 297
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $360.29 across 20 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $360.2920

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2018 $820.9949
2019 $591.5838
2020 $765.8546
2021 $951.9564
2022 $759.4250
2023 $522.6630
2024 $360.2920

Records — PY2024 (20)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1097333573 Novo Nordisk Inc $20.50 12/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103279649 ABBVIE INC. $21.39 04/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104211423 AstraZeneca Pharmaceuticals LP $15.53 10/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104212675 AstraZeneca Pharmaceuticals LP $16.72 08/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104479038 AstraZeneca Pharmaceuticals LP $18.64 02/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104771888 AstraZeneca Pharmaceuticals LP $17.27 05/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105788406 AstraZeneca Pharmaceuticals LP $21.70 06/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114005416 Regeneron Healthcare Solutions, Inc. $18.84 07/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114585514 Exact Sciences Corporation $17.61 01/30/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114585518 Exact Sciences Corporation $17.67 05/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114585522 Exact Sciences Corporation $18.85 07/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1120093673 Kerecis Limited $19.30 02/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1136164594 Lilly USA, LLC $16.60 10/03/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144593944 Xeris Pharmaceuticals, Inc. $16.35 01/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144593946 Xeris Pharmaceuticals, Inc. $16.66 03/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144593948 Xeris Pharmaceuticals, Inc. $16.76 04/16/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144593950 Xeris Pharmaceuticals, Inc. $15.49 05/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147303518 Mylan Specialty L.P. $19.66 09/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1147374246 Mylan Specialty L.P. $16.05 05/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1153705838 Salix Pharmaceuticals, a division of Bausch Health US, LLC $18.70 12/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.